POLISCOPE
Back to feed
HR4115FEDERALIN_COMMITTEE
High Impact

Lower Drug Costs for Families Act (H.R. 4115)

Original title: Lower Drug Costs for Families Act

December 17, 2024

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Where This Stands

Introduced
Committee
Floor Vote
Passed
Signed

Currently IN_COMMITTEE. The next step in the legislative lifecycle is Floor Vote.

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

The Frame

What this does

The bill changes the financial obligations of pharmaceutical manufacturers by requiring them to pay inflation rebates on a broader range of drug sales, which could influence drug pricing strategies for both Medicare and commercial health insurance markets.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Pharmaceutical manufacturers

They are required to pay inflation rebates on a wider range of drug units and calculate those rebates based on a 2016 base year.

Medicare Part B and Part D enrollees

They are affected by changes to the rebate structure that influences the pricing and availability of drugs covered under these programs.

What changed

Current stage: IN_COMMITTEE.

What's next

Floor Vote.

Background

  • This bill seeks to build upon the drug pricing provisions established in the Inflation Reduction Act of 2022 (Public Law 117-169). context

Summary

This bill expands the scope of prescription drug inflation rebates to include drugs sold in the commercial market and adjusts the base year for calculating these rebates to 2016. By changing how rebates are calculated and applied, the legislation aims to increase the number of drug units subject to inflation-based price controls under Medicare.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Why It Matters

The bill changes the financial obligations of pharmaceutical manufacturers by requiring them to pay inflation rebates on a broader range of drug sales, which could influence drug pricing strategies for both Medicare and commercial health insurance markets.

Frequently Asked Questions

What is an inflation rebate for prescription drugs?
It is a financial penalty or rebate that pharmaceutical manufacturers must pay if the price of their drug increases faster than the rate of inflation.
How does this bill change the base year for calculations?
It moves the reference year for calculating price increases from 2021 back to 2016, which generally captures a longer period of price changes for rebate purposes.
Does this affect drugs bought outside of Medicare?
Yes, the bill explicitly expands the application of these inflation rebates to drugs furnished in the commercial market.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Lobbying Activity

AARP

$4,110,000

2026

HEALTH ISSUESMEDICARE/MEDICAIDLAW ENFORCEMENT/CRIME/CRIMINAL JUSTICEPHARMACY

P.L. 119-21, One Big Beautiful Bill Act H.R. 8867, Planning for Long-term Aging Needs (PLAN) Act H.R. 5861, Legacy Act of 2025 H.R. 9393, the Lower Costs, More Transparency Act. H.R. 9396, the Prior Authorization Accountability Act. S. 4916, the Aging with Artificial Intelligence Act. H.R. 8100, Safe Staffing Saves Lives Act. S. 3886, Nurses Belong in Nursing Homes Act. H.R. 6766/S. 3492, the Essential Caregivers Act of 2025. H.R. 7966/S. 4118, Hospice Care Accountability, Reform, and Enforcement (Hospice CARE) Act. S. 2120, the Older Americans Act Reauthorization Act of 2025 H.R. 5575, the Firefighters Assisting Seniors to Emergency Response (FASTER) Act of 2025. H.R. 3954/S. 4641, Improving Access to Medicare Coverage Act. H.R.5554/S.2831, Stand Strong for Medicare Act. S. 3439/H.R. 6735, Connecting Caregivers to Medicare Act and efforts related to the bill S. 1227/H.R. 2491, Alleviating Barriers for Caregivers Act S. 668/H.R. 3183, Supporting Access to Falls Education and Prevention and Strengthening Training Efforts and Promoting Safety Initiatives (SAFE STEPS) for Veterans Act of 2025 CMS-1851-P, Hospice Proposed rule. CMS-1843-P, Skilled Nursing Facility Proposed rule. CMS-1844-P, Home Health Proposed rule. No bill number. Health care transparency. No bill number. Discussed use of artificial intelligence and health data technology. No bill number. Discussed health-related policies and activities around the fall respiratory virus season. No bill number. Discussed health insurance affordability proposals. No bill number. Discussed Nursing Home staffing standards, safety, and quality. No bill number. Discussed Nursing home transparency and ownership requirements. No bill number. Discussed home health, hospice, and long-term care. No bill number. Discussed falls prevention. No bill number. Discussed social isolation. No bill number. Discussed HUD Assisted Living Requirements No bill number. Discussed family caregiving. No bill number. Discussed AARP paper on Medicare Caregiver Training Services. No bill number. Discussed Medicaid community engagement interim final rule, including the family caregiver exemption. No bill number. Discussed the paid direct care workforce in long-term care. No bill number. Discussed the unaffordability of long-term care. No bill number. Discussed Money Follows the Person Rebalancing Demonstration Program and Medicaid HCBS spousal impoverishment protections. No bill number. Discussed Medicaid fraud and family caregivers, Medicaid self-direction programs. No bill number. Discussed sandwich generation family caregiver hearing and submitted a statement for the record discussing family caregivers and sandwich generation caregivers, programs that support them, AARP caregiving resources, and federal policies to support sandwich generation caregivers and caregivers more broadly. No bill number. Discussed long-term care. No bill number. CMS-2453-NC; Medicaid Program; 2028 Medicaid Home and Community-Based Services Quality Measure Set Submitted comments No bill number. Discussed expanding access to home care. No bill number. Discussed the increasing cost of home care No bill number. Discussed HSA use for telehealth chronic care management services/subscriptions. No bill number. Discussed artificial intelligence and technology

Sponsors

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Expansion of Inflation Rebates

The bill represents a significant policy shift by extending Medicare-style inflation rebates to the commercial market, effectively using federal authority to influence private sector drug pricing.

Connected Entities

otherMs. SlotkinmentionedMap →
otherMr. GallegomentionedMap →

Analysis Score

0–100
  • Significance80
    How much this matters to a regular citizen
  • Controversy65
    Intensity of disagreement among stakeholders
  • Entertainment10
    Compellingness for a non-policy-wonk reader
  • Buzz30
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record